Boston Scientific Corporation

NYSE:BSX

Market Cap

USD 154.72 B

Share Price

USD 104.58

Avg Daily Volume

8,321,877

Change (1 day)

0.28%

Change (1 year)

35.64%

Change (YTD)

17.09%

Boston Scientific Corporation Market Capitalization on June 26, 2025: USD 154.72 B

Boston Scientific Corporation Market Capitalization is USD 154.72 B on June 26, 2025, a 36.56% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.
  • Boston Scientific Corporation 52-week low Market Capitalization is USD 157.80 B on June 26, 2025, which is 1.99% above the current Market Capitalization.
  • Boston Scientific Corporation 52-week low Market Capitalization is USD 107.38 B on June 26, 2025, which is -30.60% below the current Market Capitalization.
  • Boston Scientific Corporation average Market Capitalization for the last 52 weeks is USD 135.44 B.
Key data
Date Market Capitalization Share Price Share Price Price to Earnings Ratio (P/E)
Market news
Loading...
NYSE: BSX

Boston Scientific Corporation

CEO Mr. Michael F. Mahoney
IPO Date May 19, 1992
Location United States
Headquarters 300 Boston Scientific Way
Employees 53,000
Sector 🏥 Health Care
Industries
Description

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Similar companies

DXCM

DexCom, Inc.

USD 85.04

0.43%

EW

Edwards Lifesciences Corporation

USD 77.15

0.23%

STE

STERIS plc

USD 238.53

-0.77%

SYK

Stryker Corporation

USD 390.40

-0.47%

ABT

Abbott Laboratories

USD 133.67

-2.71%

MDT

Medtronic plc

USD 86.18

0.24%

ZBH

Zimmer Biomet Holdings, Inc.

USD 91.74

-1.13%

ZIMV

ZimVie Inc.

USD 9.00

0.45%

StockViz Staff

June 28, 2025

Any question? Send us an email